Hanmi Pharm. Co., Ltd. Logo

Hanmi Pharm. Co., Ltd.

Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.

128940 | KO

Overview

Corporate Details

ISIN(s):
KR7128940004
LEI:
Country:
South Korea
Address:
경기도 화성시 팔탄면 무하로 214, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hanmi Pharmaceutical Co., Ltd., established in 1973, is a leading South Korean biopharmaceutical company with a strong focus on research and development. The company develops, manufactures, and markets a broad portfolio of in-house medicines, including prescription drugs, over-the-counter (OTC) products, medical supplies, and raw materials. Hanmi is recognized for its innovative drug development, particularly in the therapeutic areas of diabetes and cancer, and is committed to providing advanced medical solutions to healthcare professionals and patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-09-03 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항
Korean 13.3 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 46.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.4 MB
2025-08-14 00:00
Interim Report
[기재정정]반기보고서 (2025.06)
Korean 3.5 MB
2025-08-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 59.1 KB
2025-08-01 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 31.0 KB
2025-07-28 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.0 KB
2025-07-25 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.5 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 92.2 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.4 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 53.2 KB
2025-07-01 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-06-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.8 KB

Automate Your Workflow. Get a real-time feed of all Hanmi Pharm. Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hanmi Pharm. Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hanmi Pharm. Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.